

Founded in 1994, DiagnoCure is a life sciences company commercializing high-value cancer diagnostic tests and laboratory services that increase clinician and patient confidence in making critical treatment decisions.

DiagnoCure's strategy: genomic tests to answer unmet clinical needs

Benefiting from genomic biology research, DiagnoCure applies its expertise towards exploring the development of new diagnostic tests for the detection and management of cancer, to answer unmet clinical needs with a personalized approach focused on the patient. In addition to its own research, the Company acquires or in-licenses promising cancer biomarkers from both academic and commercial institutions.

DiagnoCure minimizes time to market in order to introduce innovative diagnostic products, including laboratory developed tests (LDT), analyte specific reagents (ASRs) and *in vitro* diagnostics (IVDs), to targeted markets.

In order to achieve a leadership position in the promising new market of molecular diagnostics, DiagnoCure focuses on a business model with four imperatives: a focused clinical field (cancer); commercial access to the market (CLIA service laboratory); a critical mass of proprietary products and favorable access to capital.

OBJECTIVES AND MILESTONES

07-08 MILESTONES

- Focus on cancer molecular diagnostics
- Additional financing of \$25 million
- Acquired Dx rights to the GCC marker for colorectal cancer
- Acquired Shc proteins
- Certification of U.S. CLIA service laboratory
- Launch of Previstage™ GCC Colorectal Cancer Staging Test
- PCA3 studies published and significant growth of sales in Europe

09 MILESTONES

- Major study in JAMA demonstrating GCC clinical potential
- PIONEER GCC observational study initiated
- Agreement with Lab21 for the distribution of Previstage™ GCC in the UK and Ireland
- Strong sales growth of the PCA3 prostate cancer marker in Europe and the U.S.
- Renewed collaboration with Gen-Probe to make PCA3 a worldwide success
- Gen-Probe invests US\$ 5 million in DiagnoCure
- PROGNSA® PCA3 FDA clinical trial initiated

2010 OBJECTIVES

- Conclude partnerships and distributorships to leverage commercial potential of DiagnoCure's pipeline
- Obtain contractual reimbursement of Previstage™ GCC from payors
- Advance clinical studies / publications to further demonstrate the clinical utility of the GCC marker
- Gen-Probe to complete its PCA3 clinical study aimed at securing FDA approval
- Maintain strong balance sheet

FINANCIAL PROFILE Q2 / April 30, 2010

• Symbol	CUR (TSX)
• Fiscal year-end	October 31
• 52-Week Range	\$0.75- \$1.48
• Common Shares outstanding	42.9 million
• Preferred Shares outstanding	4.9 million
• Market capitalization	\$58.4 million

ANALYST COVERAGE

- Bloom Burton & Co
- National Bank Financial
- Versant Partners

INVESTOR RELATIONS

Frédéric Boivin
Senior Director,
Finance & Administration
DiagnoCure, Inc.
2050 René-Lévesque Blvd. W., 6th floor
Québec (Québec) G1V 2K8 Canada
(418) 527-6100

BOARD OF DIRECTORS

Michel E. Côté
Corporate Director

Yves Fradet, M.D., FRCS(c)
Chairman of the Board,
President and Chief Medical
Officer, DiagnoCure, Inc.

Paul Gobeil, FCA
Lead Director, DiagnoCure, Inc.
Vice Chairman of the Board,
Metro, Inc.

Alain G. Michel
Chairman of the Board, Cari-All
Group, Inc.

Louise Proulx, Ph.D.
Vice President, Product
Development, ViroChem
Pharma, Inc.

Mario Thomas, Ph.D.
Managing Director, Centre for
Commercialization of Research,
Ontario Centres of Excellence

Vincent R. Zurawski, Jr., Ph.D.
President and CEO, Varinel, Inc.

MANAGEMENT TEAM

Yves Fradet, M.D., FRCS(c)
President and
Chief Medical Officer

Frédéric Boivin
Senior Director, Finance and
Administration

Paule De Blois, MBA
Senior Vice President,
Operations

Valerie B. Palmieri
President, DiagnoCure Oncology
Laboratories

John C. Schafer
Head, U.S. Commercial
Operations

GCC MARKER FOR COLORECTAL CANCER (CRC)

- Colorectal cancer is the second most fatal form of cancer, with an overall 5-year survival rate of 64%. 174,000 new diagnostics and 31,000 deaths each year in North America.
- DiagnoCure holds the exclusive worldwide diagnostic rights to the GCC marker.
- Two N.I.H.-sponsored studies initiated; the results of the first study were published in JAMA (Feb. 18, 2009), demonstrating that GCC is the strongest predictor of CRC recurrence.
- A study on 123 stage II CRC patients (Journal of Clinical Path. 05-2010) demonstrated that patients who had at least one GCC positive lymph node were two times more likely to experience disease recurrence than patients who had no GCC positive lymph nodes.
- DiagnoCure Oncology Laboratories, a subsidiary of DiagnoCure Inc., launched in 2008 the Previstage™ GCC Colorectal Cancer Staging Test, the first GCC-based molecular test for the management of colorectal cancer.

PCA3 MARKER FOR PROSTATE CANCER

- Most frequent cancer and second leading cause of cancer death in men.
- DiagnoCure owns full worldwide rights on PCA3 and has out-licensed diagnostic rights to Gen-Probe (NASDAQ : GPRO).
- Approximately 30 peer-reviewed publications support the potential clinical utility of the PCA3 test.
- Two studies of 2,400 patients, originating from GSK's REDUCE trial, showed that PCA3 can help decide about repeat prostate biopsies and predict cancer severity (ASCO GU, March 2010).
- European study of 516 men showed the utility of PCA3 before the initial biopsy, which could reduce biopsies by 40% while missing only 5% of the high grade cancers (A. de la Taille, EAU 2010).
- Multi-practice study of 1,900 men concluded that PCA3 can predict the outcome of the initial biopsy better than PSA (Crawford, AUA 2010)
- Gen-Probe completed in April 2010 a 500-patient clinical trial aimed at securing FDA approval for its PROGENSA® PCA3 test. On target to submit to the FDA by year-end 2010.
- PCA3-based tests now available through many American, European and Canadian laboratories.
- Estimated market of 1.8 million tests per year in North America and Europe (second biopsy).

SHC PROTEINS FOR FIVE TUMOR TYPES

- Acquisition in August 2007 of Catalyst Oncology and its proprietary tests.
- The Shc protein-based tests have been validated in multiple clinical studies involving patients with five tumor types, including breast and colon.
- Results have shown the tests to be strong indicators for a patient's risk of disease recurrence, as well as predictors of response to certain cancer therapies.

DiagnoCure Inc.

2050 René-Lévesque Blvd . West, 6th Floor
Québec (Québec) G1V 2K8 Canada

www.diagnocure.com
communications@diagnocure.com

Phone: (418) 527-6100

Toll Free: 1 (888) 900-6626 (Canada & US)

Fax: (418) 527-0240

This document contains forward-looking statements that involve known and unknown risks, uncertainties and assumptions that may cause actual results to differ materially from those expected. By their very nature, forward-looking statements are based on expectations and hypotheses and also involve risks and uncertainties, known and unknown, many of which are beyond DiagnoCure's control. As a result, investors are cautioned not to place undue reliance on these forward-looking statements. The forward-looking statements regarding the outcome of research and development projects, clinical studies and future revenues are based on management expectations. In addition, the reader is referred to the applicable general risks and uncertainties described in DiagnoCure's most recent Annual Information Form under the heading "Risk Factors". DiagnoCure undertakes no obligation to publicly update or revise any forward-looking statements contained herein unless required by the applicable securities laws and regulations.